This month, our experts connected with professionals worldwide at four major conferences! 🌍 ✅ASMS Mass Spectrometry Symposium Meeting hosted by CFABS in Montréal ✅OBN (UK) Ltd Awards 2024 in London ✅Rencontre Phases Précoces en Cancérologie in Paris. ✅International Pharmaco-EEG Society (IPEG) in Turkey. A big thank you to everyone who stopped by to chat with our experts! We look forward to seeing you at future events! #Clinicaltrials
Biotrial’s Post
More Relevant Posts
-
The multi-national RESOLVE-AF trial enrolled its first patient in the EU today as Dr. Max Liebregts and Dr. Lucas Boersma completed the first case at St. Antonius Hospital Nieuwegein, The Netherlands. Boersma, the European PI for the international trial said, “I’m excited to participate in this study to evaluate Cortex’s EGF mapping as a promising approach to identify extra-pulmonary vein EGF sources and their phenotypes." RESOLVE-AF is a prospective, international, multi-center trial to evaluate the use of the OptiMap™ System and OptiMap™ Catheter to identify extra-pulmonary vein EGF sources and their phenotypes. #EPeeps, #AFablation
To view or add a comment, sign in
-
-
🌎🔬 Don’t Miss AMRA Medical at ICFSR 2024! 🔬🌎 This week, the AMRA Medical team will be in attendance at the 14th annual International Conference on Frailty and Sarcopenia Research (ICFSR), where our scientists will be showcasing their latest insights into muscle composition's critical role in various health outcomes. The presentations demonstrate the utility of AMRA's MRI-based body composition analysis platform, AMRA® Researcher, in delivering novel biomarkers that describe overall muscle health. This innovative approach is transforming muscle composition research by enabling more personalized insights on function and performance. By advancing disease research in neuromuscular, metabolic diseases, and beyond, AMRA Medical continues to lead with cutting-edge MRI-powered analyses, offering more personalized insights for researchers, patients, and providers alike. Stay tuned for more updates on how we're advancing disease research with our precision imaging platform in sarcopenia and beyond! To get in touch or if you are attending and want to meet us at ICFSR, reach out to info@amramedical.com. #ICFSR2024 #AMRAMedical #MuscleComposition #ChronicKidneyDisease #Sarcopenia #precisionmedicine #neuromusculardisease #MRI #clinicalresearch
To view or add a comment, sign in
-
-
In this special #WCLC24 episode of #LungCancerConsidered, host Dr. Stephen Liu discusses daily highlights from the conference. #IASLC President Elect Dr. Caicun Zhou discusses the results of ivonescimab versus pembrolizumab in the first-line HARMONi-2 study. Dr. Tina Cascone discusses preliminary outcomes from the perioperative NeoCOAST-2 study, and Dr. Marina Chiara Garassino outlines the potential QCS-NMR TROP2 biomarker using data from TROPION-Lung01. Dr. Matthew Smeltzer shares the results of the 2024 IASLC Global Survey on Biomarker Testing and how they compare to findings from the previous survey in 2018. Listen Now: https://bit.ly/WCLC24Sun #LCSM #IASLC50
To view or add a comment, sign in
-
-
Today, we celebrate #WorldHealthDay, and the efforts of the CLINSPECT-M consortium to integrate mass spectrometry-based #proteomics into systems medicine by developing of standardized start-to-finish, fit-for-purpose workflows for clinical specimens. Testing different #samplepreparation and MS protocols on two clinically relevant sample matrices (plasma and cerebrospinal fluid), the six study partners conducted two studies, implementing the most promising protocols from the first round into the second. It was a great example of how the expert-driven exchange of knowledge and best practices can result in direct practical improvements that benefit the scientific community and, ultimately, patients. And it was especially gratifying to see our iST-BCT and SP3-iST kits do so well! Read more about the study and its results: https://ow.ly/wfVw50R3o5k
To view or add a comment, sign in
-
-
Starting to organize, with colleagues and friends, workshops and scientific sessions of this outstanding International Congress : the new edition of Roma Pain Days (April 2025). Don’t miss it #pain #paintherapy #neurosurgery #terapiadolore #dolore #neuromodulation #spine #endoscopy #spinalendoscopy #diabetes #spinalcordstimulation
Abdallah Allam Tolga Ergönenç Dr Marco Narvaez Daniele Battelli Avetis Avetisyan Rinaldi Riccardo stefano meloncelli Marco Mercieri, MD, PhD Joseph Pergolizzi, MD Sonia Khalbous Panagiotis Zis Magdi hanna Magdi R. Iskander Narinder Rawal Eleni Moka, MD, PhD, MSc, EDRA Roberto Gazzeri Dra. Rocio Guillen Diego Fornasari Anthony Dickenson MENARINI Group Menarini Asia-Pacific Berlin-Chemie Menarini Viatris Abbott Medtronic Pain Interventions #RPD-5 (April 10-12, 2025), the new edition of the Roma Pain Days congress will impress you with scientific sessions and workshops. Once again, you will have the possibility to be present in a magnificent location or take the advantage of the online event. Do not miss it!
To view or add a comment, sign in
-
-
CLIA is in our blood. Well, actually it’s on our wall, literally. We got our CLIA-registration earlier this year, and we’ve got the certificate hung proudly at our SLC office. More importantly, our high-dimensional mass cytometry and spectral flow panels are CLIA-validated. Why is that important? For our customers, that means they can be confident that the immune cell changes they see from the TokuProfile reflect actual (biological) changes in patients, opposed to variation in lab or process error. In our validation, we achieved an average coefficient of variance (CV) of 3-7% in all experiments with three health donors profiled, compared to the industry standard of 25% for intra- and inter-run precision tests. But check out our CLIA reports for yourself - links below! https://lnkd.in/gDmNnx2E https://lnkd.in/gt7DqfpY https://lnkd.in/gPPHHCip #CLIA #cytometry
To view or add a comment, sign in
-
-
#SHINE_TRAUMA trial is out ! Very proud of the results and the collaboration, many thanks to all participating sites Rigshospitalet 💪 Aahus Universitets Hospital. 💪 Odense University Hospital 💪 Oslo University Hospital 💪, and the investigators and their personel 👊 We are very humble & grateful for the support from the patients❤️ and their relatives❤️ The very reason for doing research❤️ Endotheliopathy of trauma has poor outcome. We conducted a Scandinavian multicenter RCT investigating 72hour low dose prostacyclin vs placebo infusion in 229 shocked, severely injured bleeding patients requiring requiring a median of 4 U of red blood cells, 6 U of plasma, and 2 U of platelets concentrates in the first 24 hours after hospital admission. We saw no significant difference in the mean number of ICU-free days alive <28 days, but found an important, significant reduction in hospital stay 👉Prostacyclin-treated patient stayed 8 fewer days in hospital (reduced from 27 to 20 days 💪 ). This effect was even stronger in patients surviving, in younger patients and in patients with massive injury 💪, and no harm was seen. Many thanks for the support: Funded by the Danish Regions Medicinpuljen Danske Regioner - Danish Regions 🤝 and Novo Nordisk Fonden Novo Nordisk Foundation 🤝 LINK to paper: https://lnkd.in/dw5W3_m7
To view or add a comment, sign in
-
-
Very proud of being part of this multicenter RCT in hemorrhagic TRAUMA patients 🩸- the RESULTS are out NOW 💫 We conducted a Scandinavian multicenter RCT investigating 72hour low dose prostacyclin vs placebo infusion in 229 shocked, severely injured bleeding patients requiring requiring a median of 4 U of red blood cells, 6 U of plasma, and 2 U of platelets concentrates in the first 24 hours after hospital admission. We saw no significant difference in the mean number of ICU-free days alive <28 days, but found an important, significant reduction in hospital stay 👉Prostacyclin-treated patient stayed 8 fewer days in hospital (reduced from 27 to 20 days). This effect was even stronger in patients surviving, in younger patients and in patients with massive injury 💪, and no harm was seen. LINK to paper: https://lnkd.in/dw5W3_m7
#SHINE_TRAUMA trial is out ! Very proud of the results and the collaboration, many thanks to all participating sites Rigshospitalet 💪 Aahus Universitets Hospital. 💪 Odense University Hospital 💪 Oslo University Hospital 💪, and the investigators and their personel 👊 We are very humble & grateful for the support from the patients❤️ and their relatives❤️ The very reason for doing research❤️ Endotheliopathy of trauma has poor outcome. We conducted a Scandinavian multicenter RCT investigating 72hour low dose prostacyclin vs placebo infusion in 229 shocked, severely injured bleeding patients requiring requiring a median of 4 U of red blood cells, 6 U of plasma, and 2 U of platelets concentrates in the first 24 hours after hospital admission. We saw no significant difference in the mean number of ICU-free days alive <28 days, but found an important, significant reduction in hospital stay 👉Prostacyclin-treated patient stayed 8 fewer days in hospital (reduced from 27 to 20 days 💪 ). This effect was even stronger in patients surviving, in younger patients and in patients with massive injury 💪, and no harm was seen. Many thanks for the support: Funded by the Danish Regions Medicinpuljen Danske Regioner - Danish Regions 🤝 and Novo Nordisk Fonden Novo Nordisk Foundation 🤝 LINK to paper: https://lnkd.in/dw5W3_m7
To view or add a comment, sign in
-
-
Model based meta-analysis (#MBMA) is one of the most impactful tools in our #pharmacometrics toolkit. (Yes, I will continue to beat that drum🥁) Are you going to #PAGE2024 and do you want to know more about MBMA? Come and visit the three posters of innovative work we have done in collaboration with #MSD, and stop by booth 23&24 for more information!
Certara is proud to showcase our scientific excellence at PAGE 2024. We are honored to share the following posters reflecting our work using 𝗺𝗼𝗱𝗲𝗹 𝗯𝗮𝘀𝗲𝗱 𝗺𝗲𝘁𝗮-𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀. ▶️ Understanding onset and response of two key endpoints in Systemic Lupus Erythematosus https://lnkd.in/eCKjKzdZ ▶️ Clinical Model-Based Meta-Analysis applied to Vaccine Development for SARS-CoV-2 Variants https://lnkd.in/eAGediYe ▶️ Comparative assessment of incretin therapies on weight loss through a model-based meta-analysis approach https://lnkd.in/e9HyKrNJ
To view or add a comment, sign in
-
-
🚨 New White Paper Alert! 🚨 In honor of Pulmonary Fibrosis Awareness Month, we’re excited to announce the release of "Advancing Pulmonary Fibrosis Awareness: Developing Microphysiological Systems for Effective Drug Discovery and Therapeutic Interventions," authored by our Chief Scientific Officer, Cecilia Sanchez, PhD. This white paper dives into the critical components needed to build Microphysiological Systems (MPS) that accurately model pulmonary fibrosis. It’s a must-read for scientists dedicated to discovering new therapies and advancing the fight against this devastating disease. Explore the paper and join us in raising awareness and accelerating research to combat pulmonary fibrosis. Learn more about pulmonary fibrosis from Pulmonary Fibrosis Foundation! https://lnkd.in/gxdPgcR #PulmonaryFibrosisAwareness #DrugDiscovery #MicrophysiologicalSystems #MPS #PulmonaryResearch #ObatalaSciences #TherapeuticInterventions #PulmonaryFibrosis #HumanDerivedBiomaterials
To view or add a comment, sign in